The HDAC6 inhibitor ACY‑1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells

International Journal of Oncology
Dong Hoon LeeSo Hee Kwon

Abstract

ACY‑1215, also known as ricolinostat, is a leading histone deacetylase 6 inhibitor, which is currently being tested in clinical trials for hematological malignancies. Previous studies have reported that ACY‑1215 is not potent enough as a monotherapy for the treatment of colorectal cancer (CRC), which generally requires combination therapy for successful treatment. Therefore, the present study aimed to determine whether the synergistic interaction detected between ACY‑1215 and anticancer agents in hematological cancers could occur in solid tumors. The results of the present study indicated that ACY‑1215 exerted a potent synergistic anti-proliferative effect when used in combination with anticancer agents in CRC cells. The combination of ACY‑1215 and oxaliplatin was more potent than either drug alone, as indicated by an increase in apoptotic cells and their effects on the apoptotic pathway; ACY‑1215 and oxaliplatin cotreatment activated caspase‑3 and poly (ADP ribose) polymerase, increased B‑cell lymphoma (Bcl)‑2 homologous antagonist/killer expression, and decreased Bcl‑extra large protein, phosphorylated-extracellular signal-regulated kinase and phosphorylated-protein kinase B expression. In addition, combined treatment of ACY‑...Continue Reading

References

May 25, 2002·Nature·Charlotte HubbertTso-Pang Yao
Apr 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·Stephen J HaggartyStuart L Schreiber
Nov 8, 2005·The Journal of Biological Chemistry·Yu ZhangPatrick Matthias
Sep 6, 2007·Genes & Development·Cyril BoyaultSaadi Khochbin
Dec 7, 2007·Bioorganic & Medicinal Chemistry Letters·David J WitterThomas A Miller
Jan 9, 2008·Molecular and Cellular Biology·Yu ZhangPatrick Matthias
Apr 17, 2008·Journal of Medicinal Chemistry·Guillermina EstiuOlaf Wiest
Dec 30, 2008·Bioorganic & Medicinal Chemistry Letters·David V SmilRobert Déziel
May 22, 2009·Journal of Cellular Biochemistry·P A Marks, W-S Xu
Jul 15, 2009·Biochemical and Biophysical Research Communications·Sylwia FlisJacek Spławiński
Jul 22, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Ahmedin JemalElizabeth M Ward
Nov 4, 2011·ACS Chemical Biology·Elizabeth S InksC James Chou
Jun 26, 2012·Biochemical Pharmacology·Sabrina DallavalleFranco Zunino
Sep 27, 2012·Journal of Medicinal Chemistry·Joel A BergmanAlan P Kozikowski
Jan 17, 2013·British Journal of Cancer·M KaliszczakE O Aboagye
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Aug 19, 2014·Nature Reviews. Drug Discovery·Katrina J Falkenberg, Ricky W Johnstone
Feb 20, 2015·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Emily Ashjian, Kimberly Redic
Jan 6, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dan T VoglSagar Lonial

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.